Resolution Criteria

This market will resolve to the first year in which the Reversible Inhibition of Sperm Under Guidance (RISUG) procedure becomes commercially available to the general public. "Commercially available" is defined as the procedure being offered by licensed medical practitioners outside of clinical trial settings, with necessary regulatory approvals in place. The resolution will be based on official announcements from regulatory bodies or reputable medical institutions confirming the availability of RISUG for public use.

Background

RISUG is a non-hormonal male contraceptive developed in India, involving an injection into the vas deferens to block sperm transport. Clinical trials have demonstrated its efficacy and safety, with a reported 97% success rate in preventing pregnancy. As of 2023, RISUG has completed Phase III clinical trials in India and is awaiting regulatory approval from the Drug Controller General of India (DCGI). (allthatsinteresting.com)

Considerations

While RISUG has shown promise, its commercial availability depends on regulatory approvals, manufacturing scalability, and public acceptance. Additionally, similar contraceptive methods like Vasalgel are under development in other countries, which may influence the timeline and adoption of RISUG globally.